EP4 agonists as therapeutic compounds

Patent metadata

Field	Value
Publication number	US-10407382-B2
Application number	US-201815899867-A
Country	US
Kind code	B2
Filing date	Feb 20, 2018
Priority date	Jun 6, 2014
Publication date	Sep 10, 2019
Grant date	Sep 10, 2019

Abstract

Described herein are compounds that are EP 4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of EP 4 receptors.

First claim

What is claimed is:

1. A compound selected from the group consisting of:

and pharmaceutically acceptable salts, diastereomers, and enantiomers thereof.

2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt, diastereomer, or enantiomer thereof, and a pharmaceutically acceptable carrier.

3. A method of treating glaucoma, the method comprising administering an effective amount of the compound of claim 1 to an individual in need thereof.

4. A compound selected from the group consisting of:

and pharmaceutically acceptable salts, diastereomers, and enantiomers thereof.

5. A pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier.

6. A method of treating glaucoma, the method comprising administering an effective amount of the compound of claim 4 to an individual in need thereof.

Assignees

• Allergan Inc

Inventors

• Old David W
• Hein christopher d

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P27/06

  Antiglaucoma agents or miotics · CPC title

• A61K31/164

  of a carboxylic acid with an aminoalcohol, e.g. ceramides · CPC title

• C07C233/63 Primary

  having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups · CPC title

• C07C2601/16

  the ring being unsaturated · CPC title